Forte Biosciences Stock Performance
| FBRX Stock | USD 8.17 0.63 8.36% |
The firm shows a Beta (market volatility) of 1.21, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Forte Biosciences will likely underperform. At this point, Forte Biosciences has a negative expected return of -1.13%. Please make sure to confirm Forte Biosciences' treynor ratio, accumulation distribution, as well as the relationship between the Accumulation Distribution and period momentum indicator , to decide if Forte Biosciences performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Forte Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
One Day Return 8.36 | Five Day Return 37.54 | Year To Date Return (67.67) | Ten Year Return (99.83) | All Time Return (99.83) |
Last Split Factor 1:25 | Dividend Date 2020-06-16 | Last Split Date 2024-08-28 |
1 | Disposition of 1250 shares by Paul Wagner of Forte Biosciences subject to Rule 16b-3 | 12/31/2024 |
2 | Disposition of 375 shares by Riley Antony A of Forte Biosciences subject to Rule 16b-3 | 01/02/2025 |
3 | Forte Biosciences Is a Great Choice for Trend Investors, Heres Why | 01/03/2025 |
4 | Forte Biosciences expands equity incentive plan | 01/24/2025 |
5 | Disposition of 2593 shares by Chen Hubert C of Forte Biosciences at 1.01 subject to Rule 16b-3 | 01/30/2025 |
6 | Forte Biosciences, Inc. to Present at Upcoming Investor Meetings | 02/03/2025 |
7 | JANUS HENDERSON GROUP PLC Acquires Significant Stake in Forte Biosciences Inc | 02/14/2025 |
8 | Forte Biosciences, Inc. Short Interest Update - MarketBeat | 02/28/2025 |
9 | Forte Biosciences, Inc. Sees Large Drop in Short Interest - Defense World | 03/14/2025 |
10 | Acquisition by Finck Barbara K of 31000 shares of Forte Biosciences at 7.02 subject to Rule 16b-3 | 03/19/2025 |
11 | Insider Trading | 03/20/2025 |
12 | Acquisition by Doberstein Stephen K of 31000 shares of Forte Biosciences at 7.54 subject to Rule 16b-3 | 03/21/2025 |
| Begin Period Cash Flow | 41.1 M |
Forte |
Forte Biosciences Relative Risk vs. Return Landscape
If you would invest 1,901 in Forte Biosciences on December 22, 2024 and sell it today you would lose (1,084) from holding Forte Biosciences or give up 57.02% of portfolio value over 90 days. Forte Biosciences is currently does not generate positive expected returns and assumes 7.4774% risk (volatility on return distribution) over the 90 days horizon. In different words, 66% of stocks are less volatile than Forte, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Forte Biosciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Forte Biosciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Forte Biosciences, and traders can use it to determine the average amount a Forte Biosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1511
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | FBRX |
Estimated Market Risk
| 7.48 actual daily | 66 66% of assets are less volatile |
Expected Return
| -1.13 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.15 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Forte Biosciences is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Forte Biosciences by adding Forte Biosciences to a well-diversified portfolio.
Forte Biosciences Fundamentals Growth
Forte Stock prices reflect investors' perceptions of the future prospects and financial health of Forte Biosciences, and Forte Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Forte Stock performance.
| Return On Equity | -1.37 | ||||
| Return On Asset | -0.68 | ||||
| Current Valuation | 39.71 M | ||||
| Shares Outstanding | 6.39 M | ||||
| Price To Book | 5.99 X | ||||
| EBITDA | (32.48 M) | ||||
| Net Income | (31.48 M) | ||||
| Cash And Equivalents | 38.55 M | ||||
| Cash Per Share | 1.89 X | ||||
| Total Debt | 3.67 M | ||||
| Current Ratio | 25.67 X | ||||
| Book Value Per Share | 6.42 X | ||||
| Cash Flow From Operations | (28.71 M) | ||||
| Earnings Per Share | (16.38) X | ||||
| Market Capitalization | 52.23 M | ||||
| Total Asset | 38.98 M | ||||
| Retained Earnings | (118.52 M) | ||||
| Working Capital | 34.66 M | ||||
About Forte Biosciences Performance
Evaluating Forte Biosciences' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Forte Biosciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Forte Biosciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.93) | (0.98) | |
| Return On Capital Employed | (0.83) | (0.87) | |
| Return On Assets | (0.93) | (0.98) | |
| Return On Equity | (0.80) | (0.84) |
Things to note about Forte Biosciences performance evaluation
Checking the ongoing alerts about Forte Biosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Forte Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Forte Biosciences generated a negative expected return over the last 90 days | |
| Forte Biosciences has high historical volatility and very poor performance | |
| Forte Biosciences has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (31.48 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Forte Biosciences currently holds about 38.55 M in cash with (28.71 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.89. | |
| Forte Biosciences has a frail financial position based on the latest SEC disclosures | |
| Over 80.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Insider Trading |
- Analyzing Forte Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Forte Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Forte Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Forte Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Forte Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Forte Biosciences' stock. These opinions can provide insight into Forte Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Forte Stock Analysis
When running Forte Biosciences' price analysis, check to measure Forte Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Forte Biosciences is operating at the current time. Most of Forte Biosciences' value examination focuses on studying past and present price action to predict the probability of Forte Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Forte Biosciences' price. Additionally, you may evaluate how the addition of Forte Biosciences to your portfolios can decrease your overall portfolio volatility.